Xencor announces Phase 1 expansion data in renal cell carcinoma and opens healthy subject study for lead bispecific antibody.
Xencor reported Q2 2026 financial results and announced that data from XmAb819 expansion cohorts in clear cell renal cell carcinoma will be presented at ESMO 2026; additionally, the company initiated a first-in-human study for its first xenlock bispecific antibody, XmAb412.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day